𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cabozantinib in Progressive Medullary Thyroid Cancer

✍ Scribed by Elisei, Rossella (author);Schlumberger, Martin J. (author);Müller, Stefan P. (author);Schöffski, Patrick (author);Brose, Marcia S. (author);Shah, Manisha H. (author);Licitra, Lisa (author);Jarzab, Barbara (author);Medvedev, Viktor (author);Kreissl, Michael C. (author);Niederle, Bruno (author);Cohen, Ezra E.W. (author);Wirth, Lori J. (author);Ali, Haythem (author);Hessel, Colin (author);Yaron, Yifah (author);Ball, Douglas (author);Nelkin, Barry (author);Sherman, Steven I. (author)


Book ID
125505508
Publisher
American Society of Clinical Oncology
Year
2013
Tongue
English
Weight
228 KB
Volume
31
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Cabozantinib in Progressive Medullary Th
✍ Elisei, Rossella (author);Schlumberger, Martin J. (author);Müller, Stefan P. (au 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 228 KB
Pretargeted radioimmunotherapy in rapidl
✍ Françoise Kraeber-Bodéré; Pierre-Yves Salaun; Aurore Oudoux; David M. Goldenberg 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB

## Abstract Medullary thyroid cancer (MTC) patients with localized residual disease and/or distant metastases may survive for several years or rapidly progress and die of their disease. Thus, highly reliable prognostic factors are needed for an early distinction between high‐risk patients who need

Medullary Thyroid Cancer
✍ Wells, Samuel A.; Moley, Jeffrey F.; You, Y. Nancy; Lakhani, Vipul 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 378 KB